A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Summary

This is a phase 1/2 multicenter, first-in-human study of IBI129. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI129, plan to enroll 22\~180 subjects, and a phase 2 to explore efficacy, safety and tolerability of IBI129 at RP2D in specified types of solid tumor. Approximately 182 evaluable subjects will be enrolled for phase 2

Timeline

Start

2024-03-12

Primary completion

2024-11-30

Completion

2025-05-31

Drugs

Indications